Stocktoria
Kymera Therapeutics, Inc. KYMR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-08-21
Chart by TradingView
3/9
Piotroski F — financial health
9.79
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$8.9B
P / B5.6×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M |
| Operating income | -$349.4M | -$261.6M | -$165.5M | -$161.3M | -$100.5M |
| Net income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$100.2M |
| Operating cash flow | -$232.9M | -$194.5M | -$102.8M | -$153.1M | -$128.9M |
| Free cash flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M | -$130.5M |
| Total assets | $1.7B | $978.0M | $575.8M | $603.1M | $605.9M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M |
| Shareholders' equity | $1.6B | $835.6M | $395.0M | $490.2M | $459.6M |
| Ratios | |||||
| Operating margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| Net margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% |
| FCF margin | -597.6% | -440.5% | -174.7% | -333.0% | -179.2% |
| Return on assets | -17.9% | -22.9% | -25.5% | -25.7% | -16.5% |
| Return on equity | -19.7% | -26.8% | -37.2% | -31.6% | -21.8% |
| Current ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 |
| Revenue growth | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.79 (safe)
- Working capital / assets 0.452
- Retained earnings / assets -0.612
- EBIT / assets -0.2
- Equity / liabilities 9.682
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001815442 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.